Abzu discovered key biomarkers for clinical trial success.
Simple models accurately predicted and explained key biomarkers for clinical trial success.
Abzu increased safe ASOs by 20% over-and-above the in-house model.
Abzu’s in-house activity models for RNA therapeutics are best-in-class for designing safe ASOs.